222551-17-9
基本信息
1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪
SLV 313
adoprazine
Unii-7snb18Q89d
Adoprazine (SLV313)
SLV 313
SLV313
SLV-313
1-(2,3-Dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)-3-pyridinyl]methyl]piperazine
Piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-[[5-(4-fluorophenyl)-3-pyridinyl]methyl]-
物理化学性质
| 沸点 | 565.0±50.0 °C(Predicted) |
| 密度 | 1.256 |
| 储存条件 | -20°C储存 |
| 溶解度 | DMSO : 50 mg/mL (123.32 mM; Need ultrasonic)H2O : < 0.1 mg/mL (insoluble) |
| 酸度系数(pKa) | 6.07±0.10(Predicted) |
| 形态 | 粉末 |
| 颜色 | Light yellow to yellow |
1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/11/08 | HY-14782 | 1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 Adoprazine | 222551-17-9 | 5mg | 1400元 |
| 2024/11/08 | HY-14782 | 1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 Adoprazine | 222551-17-9 | 10mM * 1mLin DMSO | 1540元 |
| 2024/11/08 | HY-14782 | 1-(2,3-二氢-1,4-苯并二恶烷-5-基)-4-[[5-(4-氟苯基)-3-吡啶基]甲基]哌嗪 Adoprazine | 222551-17-9 | 10mg | 2200元 |
常见问题列表
|
5-HT 1A Receptor 9 (pEC 50 ) |
D 2 Receptor 9.3 (pA2) |
D 3 Receptor 8.9 (pA2) |
D 4 Receptor 8.0 (pKi) |
5-HT 7 Receptor 7.2 (pKi) |
5-HT 1A Receptor 9.1 (pKi) |
D 2 Receptor 8.4 (pKi) |
D 3 Receptor 8.4 (pKi) |
Adoprazine (SLV313) has high affinity at human recombinant D 2 , D 3 , D 4 , 5-HT 2B , and 5-HT 1A receptors, with pK i s of 8.4, 8.4, 8.0, 7.9 and 9.1, respectively. Adoprazine (SLV313) acts as a high potency dopamine D 2 receptor antagonist and an efficacious serotonin 5-HT 1A receptor agonist, with E max value (% effect of 10 μM 5-HT) of 73 and pK B value of 8.5 .
Adoprazine (SLV313) (0.1-10 mg/kg; p.o.; single) is sufficient to reduce extracellular 5-HT and increase dopamine levels in the nucleus accumbens in a dose- and time-dependent manner.
| Animal Model: | Male Wistar rats (275-350 g) |
| Dosage: | 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg |
| Administration: | p.o.; single |
| Result: | Led to a dose- and time-dependent increase in extracellular levels of DA, DOPAC, and HVA. In contrast, led to a reduction in 5-HT levels and no change in 5-HIAA levels. |